

Clearmind Medicine's stock rose 63.9% after receiving IRB approval for its Phase I/IIa trial of CMND-100, a drug for alcohol use disorder.
You can purchase shares of AdvisorShares Psychedelics ETF (ARCA:PSIL) through any online brokerage.
There are no as such competitors for AdvisorShares Psychedelics ETF.
There is no analysis for AdvisorShares Psychedelics ETF to provide a consensus price target.
The stock price for AdvisorShares Psychedelics ETF (ARCA: PSIL) is $ last updated .
There are no upcoming dividends for AdvisorShares Psychedelics ETF.
AdvisorShares Psychedelics ETF does not have any upcoming earnings scheduled.
There is no upcoming split for AdvisorShares Psychedelics ETF.
The Fund is an actively managed exchange-traded fund (ETF) that seeks to achieve its investment objective by primarily investing in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in...